يعرض 1 - 10 نتائج من 161 نتيجة بحث عن '"Linkova, N."', وقت الاستعلام: 1.29s تنقيح النتائج
  1. 1
    دورية أكاديمية

    العلاقة: Transport of biologically active ultrashort peptides using POT and LAT carriers / V. Khavinson [et al.] // International Journal of Molecular Sciences. - 2022. - Vol.23, №14.-Art. 7733. - URL: https://www.mdpi.com/1422-0067/23/14/7733Test.; http://dspace.bsu.edu.ru/handle/123456789/52542Test

  2. 2
    دورية أكاديمية

    العلاقة: Kuznik, B.I. Oxidative stress, aging, and short peptides / B.I. Kuznik, N.S. Linkova, O.M. Ivko // Neuroscience and Behavioral Physiology. - 2022. - Vol.52, №1.-P. 183-189. - Doi:10.1007/s11055-022-01219-1. - Refer.: p. 188-189.; http://dspace.bsu.edu.ru/handle/123456789/52337Test

  3. 3
    دورية أكاديمية

    العلاقة: Sirtuins: role in the regulation of oxidative stress and the pathogenesis of neurodegenerative diseases / A.E. Pukhalskaia [et al.] // Neuroscience and Behavioral Physiology. - 2022. - Vol.52, №1.-P. 164-174. - Doi:10.1007/s11055-022-01217-3. - Refer.: p. 171-174.; http://dspace.bsu.edu.ru/handle/123456789/52336Test

  4. 4
    مؤتمر

    وصف الملف: application/pdf

    العلاقة: Проблемы развития физической культуры и спорта в новом тысячелетии : материалы VIII международной научно-практической конференции. - Екатеринбург, 2019; Бехтерева, Е. В. Причины снижения интереса студентов к занятиям физической культурой и спортом / Е. В. Бехтерева, Н. А. Линькова // Проблемы развития физической культуры и спорта в новом тысячелетии : материалы VIII международной научно-практической конференции, 28 февраля 2019 г., г. Екатеринбург / Рос. гос. проф.-пед. ун-т. - Екатеринбург : РГППУ, 2019. - С. 87-90.; https://elar.rsvpu.ru/handle/123456789/37853Test

  5. 5
    دورية أكاديمية

    المساهمون: Khavinson, V., Diomede, F., Mironova, E., Linkova, N., Trofimova, S., Trubiani, O., Caputi, S., Sinjari, B.

    وصف الملف: ELETTRONICO

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/32019204; info:eu-repo/semantics/altIdentifier/wos/WOS:000515384800179; volume:25; issue:3 / Art. 609; firstpage:1; lastpage:17; numberofpages:17; journal:MOLECULES; http://hdl.handle.net/11564/716509Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85078720452; https://www.mdpi.com/1420-3049/25/3/609Test

  6. 6
    دورية أكاديمية

    المساهمون: Исследование выполнено при спонсорской поддержке ЗАО «БИОКАД». Спонсор участвовал в разработке проекта исследования и поддержке исследовательской программы, а также в принятии решения о представлении статьи для публикации. Конфликт интересов не повлиял на результаты исследования.

    المصدر: Rheumatology Science and Practice; Vol 59, No 2 (2021); 141-151 ; Научно-практическая ревматология; Vol 59, No 2 (2021); 141-151 ; 1995-4492 ; 1995-4484

    وصف الملف: application/pdf

    العلاقة: https://rsp.mediar-press.net/rsp/article/view/3016/2074Test; Насонов ЕЛ (ред.). Российские клинические рекомендации. Ревматология. М.;2016:17-57. [Nasonov EL (ed.). Rheumatology: Russian clinical guidelines. Moscow;2019:17-57 (In Russ.)].; Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Primers. 2018;4:18001. doi:10.1038/nrdp.2018.1; Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392(10159):1789-1858. doi:10.1016/S0140-6736(17)32154-2; Smolen JS, Landewe RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685-699. doi:10.1136/annrheumdis-2019-216655; Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register. Arthritis Res Ther. 2006;8(3):R66. doi:10.1186/ar1933; Paulshus Sundlisaeter N, Olsen IC, Aga AB, Hammer HB, Uhlig T, van der Heijde D, et al. Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol. Rheumatology (Oxford). 2018;57(11):2022-2031. doi:10.1093/rheumatology/key202; Khlyabova P, Eremeeva A, Lutckii A, Dokukina E, Chernyaeva E, Ivanov R. SAT0040: Safety, tolerability, pharmacokinetics and pharmacodynamics of bcd-089, novel monoclonal anti-IL6 receptor antibody: results from the first-in-human single dose escalation study in healthy volunteers. Ann Rheum Dis. 2018;77(Suppl 2):884-885. doi:10.1136/annrheumdis-2018-eular.2410; Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569-2581. doi:10.1002/art.27584; Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727-735. doi:10.1002/art.1780380602; Heegaard C, Dreyer L, Egsmose C, Madsen OR. Test-retest reliability of the disease activity score 28 CRP (DAS28-CRP), the simplified disease activity index (SDAI) and the clinical disease activity index (CDAI) in rheumatoid arthritis when based on patient self-assessment of tender and swollen joints. Clin Rheumatol. 2013;32(10):1493-1500. doi:10.1007/s10067-013-2300-9; Bykerk VP, Massarotti EM. The new ACR/EULAR remission criteria: rationale for developing new criteria for remission. Rheumatology (Oxford). 2012;51(Suppl 6):vi16-vi20. doi:10.1093/rheumatology/kes281; van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 2000;27(1):261-263.; Genovese MC, Fleischmann R, Kivitz AJ, Rell-Bakalarska M, Martincova R, Fiore S, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: Results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424-1437. doi:10.1002/art.39093; Kivitz A, Olech E, Borofsky M, Zazueta BM, Navarro-Sarabia F, Radominski SC, et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(11):1653-1661. doi:10.1002/acr.22384; 15. Mazurov V, Zotkin E, Ilivanova E, Kropotina T, Plaksina T, Nesmeyanova O, et al. FRI0108 Shot-term efficacy of BCD-089, novel monoclonal anti-IL6 receptor antibody, in combination with methotrexate in patients with rheumatoid arthritis: 12-week results of phase 2 AURORA Study. Ann Rheum Dis. 2019;78(Suppl 2):721.; Fleischmann R, van Adelsberg J, Lin Y, Castelar-Pinheiro GD, Brzezicki J, Hrycaj P, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69(2):277-290. doi:10.1002/art.39944; Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S, et al. Sarilumab, a fully human monoclonal antibody against IL6R alpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial. Ann Rheum Dis. 2014;73(9):1626-1634. doi:10.1136/ann-rheumdis-2013-204405; Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin 6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817-2829. doi:10.1002/art.22033; Castagne B, Viprey M, Martin J, Schott AM, Cucherat M, Soubrier M. Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis. PLoS One. 2019;14(8):e0220178. doi:10.1371/journal.pone.0220178; Giles JT, Sattar N, Gabriel S, Ridker PM, Gay S, Warne C, et al. Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: A randomized controlled trial. Arthritis Rheumatol. 2020;72(1):31-40. doi:10.1002/art.41095; https://rsp.mediar-press.net/rsp/article/view/3016Test

  7. 7
    دورية أكاديمية

    العلاقة: Sirtuins expression in the hippocampus and buccal epithelium of elderly and senile individuals with Alzheimer’s disease / A.E. Pukhalskaia [et al.] // Advances in Gerontology. - 2021. - Vol.11, №2.-P. 126-131.; http://dspace.bsu.edu.ru/handle/123456789/52117Test

  8. 8
    دورية أكاديمية

    العلاقة: Khavinson, V.Kh. Peptide KED: molecular-genetic aspects of neurogenesis regulation in Alzheimer’s disease / Khavinson V.Kh., N.S. Linkova, R.S. Umnov // Bulletin of Experimental Biology and Medicine. - 2021. - Vol.171, №2.-P. 190-193.; http://dspace.bsu.edu.ru/handle/123456789/51987Test

  9. 9
    دورية أكاديمية

    العلاقة: Influence of AEDG and KE peptides on mitochondrial staining and the expression of ribosomal protein l7a with aging of the human pineal gland and thymus cell In vitro / O.M. Ivko [et al.] // Advances in Gerontology. - 2021. - Vol.11, №3.-P. 261-267.; http://dspace.bsu.edu.ru/handle/123456789/51986Test

  10. 10
    دورية أكاديمية

    العلاقة: Peptides: Prospects for Use in the Treatment of COVID-19 / V. Khavinson [et al.] // Molecules. - 2020. - Vol.25, №19.-Art. 4389. - Doi:10.3390/molecules25194389. - URL: https://www.mdpi.com/1420-3049/25/19/4389/htmTest; http://dspace.bsu.edu.ru/handle/123456789/41846Test